HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

KN38-7271 Study Group Selected Research

3- (2- hydroxymethylindanyl- 4- oxy)phenyl- 4,4,4- trifluoro- 1- sulfonate

8/2012Early survival of comatose patients after severe traumatic brain injury with the dual cannabinoid CB1/CB2 receptor agonist KN38-7271: a randomized, double-blind, placebo-controlled phase II trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


KN38-7271 Study Group Research Topics

Disease

1Traumatic Brain Injuries (Traumatic Brain Injury)
08/2012
1Coma (Comas)
08/2012
1Craniocerebral Trauma (Head Injury)
08/2012

Drug/Important Bio-Agent (IBA)

13- (2- hydroxymethylindanyl- 4- oxy)phenyl- 4,4,4- trifluoro- 1- sulfonateIBA
08/2012
1CannabinoidsIBA
08/2012
1Pharmaceutical PreparationsIBA
08/2012
1CB2 Cannabinoid ReceptorIBA
08/2012